Compare TotalEnergies SE (TTE) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TotalEnergies SE vs 10X Genomics Inc — how do they compare? TotalEnergies SE trades at $82.04 (market cap $179.99B), while 10X Genomics Inc trades at $47.2 (market cap $5.48B). The key difference: TotalEnergies SE is far larger — about 32.8× 10X Genomics Inc's market cap, and TotalEnergies SE pays a 5.22% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TTE | TXG | |
|---|---|---|
Market Cap | $179.99B | $5.48B |
Sector | Energy | Health |
52-Week High | $93.60 | $45.80 |
52-Week Low | $57.39 | $11.34 |
Enterprise Value | $214.14B | $5.02B |
Dividend Yield | 5.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TotalEnergies (TTE) trades at $83.53, up 2.63% with a bullish technical signal supported by moving averages. The stock shows attractive valuation metrics including a P/E of 11.99 and P/S of 0.96, with strong profitability margins. Recent Q1 2026 earnings beat expectations at $2.45 EPS, while analysts maintain a consensus Buy rating with $100 price target representing 20% upside potential.
TTE presents compelling value with conservative valuation and steady dividend payments, though revenue has declined from $263.3B in 2022 to $182.3B in 2025. Key risks include ongoing Middle East exposure and energy price volatility. The upcoming Q2 earnings report on July 23rd will be crucial for confirming the positive momentum.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
